Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neuroendocrine Tumors: early-phase trial registry
27 of 53 indexed Neuroendocrine Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #265 of 28,707 conditions by registered trial count.
53 US clinical trials · 27 currently recruiting · #265 of 28,707 conditions by registered trial count
Neuroendocrine Tumors: 53 US clinical trials tracked, 27 recruiting.
Neuroendocrine Tumors is the subject of 53 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition neuroendocrine-tumors
OPEN 27 | RECR 51% | LATE 3 | EARLY 40 | RANK #265 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Chronic Pancreatitis (51% recruiting · 43 trials)
Neuroendocrine Tumors lists 27 open slots (51% of 53 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neuroendocrine Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neuroendocrine Tumors is recruiting above its size-band peers.
27 of 53 indexed trials (50.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Neuroendocrine Tumors trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 6 of 53 trials (11.3%). 39 distinct sponsors appear on at least one study for this condition label.
-
Typical Neuroendocrine Tumors enrolment sits around 68 participants.
Median target enrolment is 68 among the 53 trials that report a genuine target (sentinel values excluded). 31 of those (58.5%) plan for fewer than 100 participants.
-
Neuroendocrine Tumors research is mostly interventional.
47 interventional and 6 observational studies make up this index (88.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
53 total, page 2 of 2
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
Fox Chase Cancer Center
NCT02939651
Lithium for Low-Grade Neuroendocrine Tumors
University of Wisconsin, Madison
NCT00501540
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Emory University
NCT01469572
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 19 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Neuroendocrine Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neuroendocrine Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neuroendocrine Tumors page
53 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Neuroendocrine Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Neuroendocrine Tumors trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuroendocrine Tumors condition card totals 53 registered trials; most-linked intervention Everolimus; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.